Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

A novel prostate cancer vaccine reported to induce specific immune responses

Nov. 27, 2002

New data on the immunomodulatory effects of IL-2 + histamine in advanced melanoma

Nov. 27, 2002

MLN-2704 enters phase I in androgen-independent prostate cancer

Nov. 26, 2002

Ivax to develop LMB-9

Nov. 25, 2002

IGN-311 reported safe in rhesus monkeys

Nov. 22, 2002

CC-5013 effective and well tolerated in multiple myeloma

Nov. 22, 2002

Enrollment completed for BLP25 liposomal vaccine study in non-small cell lung cancer

Nov. 19, 2002

Albuleukin superior to rIL-2 in mouse model of metastatic melanoma

Nov. 18, 2002

Potential use of vaccines in advanced prostate cancer

Nov. 15, 2002

IL-6 production inhibitors in early development at Ono

Nov. 15, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...